Open Access Highly Accessed Email this article to a friend

Rationale and design of DECISION: a double-blind, randomized, placebo-controlled phase III trial evaluating the efficacy and safety of sorafenib in patients with locally advanced or metastatic radioactive iodine (RAI)-refractory, differentiated thyroid cancer

Marcia S Brose*, Christopher M Nutting, Steven I Sherman, Young K Shong, Johannes WA Smit, Gerhard Reike, John Chung, Joachim Kalmus, Christian Kappeler and Martin Schlumberger*

BMC Cancer 2011, 11:349 doi:10.1186/1471-2407-11-349

Fields marked * are required


Multiple email addresses should be separated with commas or semicolons.
How can I ensure that I receive BMC Cancer's emails?